amifostine anhydrous has been researched along with Lung Neoplasms in 73 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
Lung Neoplasms: Tumors or cancer of the LUNG.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effect of treatments with the hypoxic cell radiosensitizers misonidazole (MISO), SR-2508, RSU-1069, and with the radioprotector WR-2721 on spontaneously disseminated Lewis lung carcinoma (LLC) and B16 melanoma (B16M) was investigated." | 7.67 | Influence of misonidazole, SR-2508, RSU-1069 and WR-2721 on spontaneous metastases in C57BL mice. ( Chapman, JD; Kanclerz, A, 1988) |
| "The effect of treatments with the hypoxic cell radiosensitizers misonidazole (MISO), SR-2508, RSU-1069, and with the radioprotector WR-2721 on spontaneously disseminated Lewis lung carcinoma (LLC) and B16 melanoma (B16M) was investigated." | 3.67 | Influence of misonidazole, SR-2508, RSU-1069 and WR-2721 on spontaneous metastases in C57BL mice. ( Chapman, JD; Kanclerz, A, 1988) |
| "The influence of tumor size on the ability of S-2-(3-aminopropylamino)ethylphosphorothioic acid (WR-2721) or misonidazole (MISO) to alter cyclophosphamide (CY) antitumor activity was investigated, using a chemically induced fibrosarcoma (FSA) and a spontaneous fibrosarcoma (NFSA) in C3Hf/Kam mice." | 3.66 | Effect of tumor size on S-2-(3-aminopropylamino)ethylphosphorothioic acid and misonidazole alteration of tumor response to cyclophosphamide. ( Hunter, N; Ito, H; Milas, L, 1983) |
| "A total of 92 patients with colorectal cancer or gastric cancer were enrolled, and randomly assigned to receive amifostine (500 mg/m2)(amifostine group, 46 patients) or glutamine (1500 mg/m2) (control group, 46 patients) just before oxaliplatin infusion." | 2.73 | [Prophylactic effect of amifostine on oxaliplatin-related neurotoxicity in patients with digestive tract tumors]. ( Fan, QX; Lu, P; Wang, LX; Wang, RL; Wang, X; Zong, H, 2008) |
| " However, patient self-assessments suggested a possible advantage to AM that is being explored with modified dosing route strategies." | 2.71 | Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01. ( Axelrod, R; Byhardt, R; Komaki, R; Langer, C; Machtay, M; Movsas, B; Nicolaou, N; Sarna, L; Scott, C; Smith, C; Wasserman, T; Werner-Wasik, M, 2005) |
| " A significantly higher Cmax was observed for patients receiving PAC + AMI versus PAC alone." | 2.71 | Influence of the cyto-protective agent amifostine on the pharmacokinetics of low-dose Paclitaxel. ( Alberola, V; Juan, O; Rocher, A; Sánchez, A; Sánchez, JJ, 2005) |
| "Acute esophagitis was scored weekly." | 2.70 | Phase II: trial of twice weekly amifostine in patients with non-small cell lung cancer treated with chemoradiotherapy. ( Axelrod, RS; Chapman, AE; Curran, WJ; Deshields, M; Friedland, DP; Grubbs, S; Hauck, W; Rose, LJ; Werner-Wasik, M, 2002) |
| " These results with a small number of patients suggest that amifostine given with carboplatin may reduce the duration of thrombocytopenia and hospitalisation." | 2.68 | Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: a randomised phase II study. ( Anderson, H; Betticher, DC; Meely, K; Oster, W; Ranson, M; Thatcher, N, 1995) |
| "Mucositis is a significant complication of cancer therapy, with important clinical and economic implications." | 2.43 | Amifostine in the management of radiation-induced and chemo-induced mucositis. ( Bensadoun, RJ; Keefe, D; Lalla, RV; Schubert, MM, 2006) |
| "Weight loss was monitored." | 1.35 | Clinically meaningful differences in patient-reported outcomes with amifostine in combination with chemoradiation for locally advanced non-small-cell lung cancer: an analysis of RTOG 9801. ( Byhardt, R; Komaki, R; Langer, C; Machtay, M; Movsas, B; Nicolaou, N; Sarna, L; Swann, S; Wasserman, T; Werner-Wasik, M, 2008) |
| "Esophagitis is a major complication of chemoradiation therapy in patients with non-small cell lung cancer, producing significant morbidity and resulting in treatment interruptions." | 1.33 | Amifostine in chemoradiation therapy for non-small cell lung cancer: review of experience and design of a phase II trial assessing subcutaneous and intravenous bolus administration. ( Langer, C; Movsas, B; Werner-Wasik, M, 2005) |
| " The dose-volume histogram (DVH) data were used to estimate the local dose-response relationship for loss of DL(CO)." | 1.32 | The relationship between local dose and loss of function for irradiated lung. ( Forster, KM; Gopal, R; Kelly, JF; Komaki, R; Liao, Z; Starkschall, G; Stevens, C; Tucker, SL, 2003) |
| "By contrast, 60% of the tumors analyzed showed a loss of IAP expression in both epithelial cells and stroma, and only 10% to 15% of them demonstrated nuclear/cytoplasmic reactivity, which was confined to the epithelial cells." | 1.31 | Down-regulation of intestinal-type alkaline phosphatase in the tumor vasculature and stroma provides a strong basis for explaining amifostine selectivity. ( Giatromanolaki, A; Koukourakis, MI; Maltezos, E; Sivridis, E, 2002) |
| "Transient hypotension was the most common side effect occurring in association with amifostine." | 1.31 | Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study. ( Genvresse, I; Harder, H; Lange, C; Possinger, K; Schanz, J; Schweigert, M; Späth-Schwalbe, E, 2001) |
| " Nontumor-bearing control animals were sham treated using the same dosing and surgery schedules." | 1.31 | Inhibition of spontaneous metastases formation by amifostine. ( Grdina, DJ; Hunter, N; Kataoka, Y; Milas, L; Murley, JS; Weichselbaum, RR, 2002) |
| " Our results confirm previous reports of the ability of amifostine to protect normal tissues from the toxic effects of chemotherapy drugs and now extend these observations to paclitaxel." | 1.30 | Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumour cells is maintained. ( Capizzi, RL; Fernandes, D; Johnson, CS; List, AF; Paine-Murrieta, GD; Taylor, CW; Wang, LM, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (8.22) | 18.7374 |
| 1990's | 13 (17.81) | 18.2507 |
| 2000's | 49 (67.12) | 29.6817 |
| 2010's | 5 (6.85) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yan, C | 1 |
| Luo, L | 1 |
| Urata, Y | 1 |
| Goto, S | 1 |
| Li, TS | 1 |
| Devine, A | 1 |
| Marignol, L | 1 |
| Han, HS | 1 |
| Han, JY | 1 |
| Yu, SY | 1 |
| Pyo, HR | 1 |
| Kim, HY | 1 |
| Cho, KH | 1 |
| Lee, DH | 1 |
| Kim, HT | 1 |
| Lee, JS | 3 |
| Lu, P | 1 |
| Fan, QX | 1 |
| Wang, LX | 1 |
| Wang, X | 1 |
| Zong, H | 1 |
| Wang, RL | 1 |
| Koukourakis, MI | 4 |
| Tsoutsou, PG | 1 |
| Abatzoglou, I | 1 |
| Movsas, B | 9 |
| Moughan, J | 1 |
| Sarna, L | 3 |
| Langer, C | 6 |
| Werner-Wasik, M | 7 |
| Nicolaou, N | 3 |
| Komaki, R | 12 |
| Machtay, M | 4 |
| Wasserman, T | 4 |
| Bruner, DW | 1 |
| Bae, K | 1 |
| Paulus, R | 1 |
| Gore, EM | 1 |
| Albain, K | 1 |
| Sause, WT | 1 |
| Curran, WJ | 2 |
| Bourhis, J | 1 |
| Blanchard, P | 1 |
| Maillard, E | 1 |
| Brizel, DM | 1 |
| Buentzel, J | 1 |
| Langendijk, JA | 1 |
| Swan Leong, S | 1 |
| Levendag, P | 1 |
| Pignon, JP | 1 |
| Wang, S | 1 |
| Zhang, Y | 1 |
| Zhang, S | 1 |
| Ma, S | 1 |
| Dubray, B | 1 |
| Dhermain, F | 1 |
| Romanidis, K | 1 |
| Froudarakis, M | 1 |
| Kyrgias, G | 1 |
| Koukourakis, GV | 1 |
| Retalis, G | 1 |
| Bahlitzanakis, N | 1 |
| Giatromanolaki, A | 2 |
| Sivridis, E | 1 |
| Maltezos, E | 1 |
| Senzer, N | 2 |
| Gopal, R | 2 |
| Tucker, SL | 2 |
| Liao, Z | 5 |
| Forster, KM | 1 |
| Stevens, C | 2 |
| Kelly, JF | 2 |
| Starkschall, G | 2 |
| Leong, SS | 1 |
| Tan, EH | 1 |
| Fong, KW | 1 |
| Wilder-Smith, E | 1 |
| Ong, YK | 1 |
| Tai, BC | 1 |
| Chew, L | 1 |
| Lim, SH | 1 |
| Wee, J | 1 |
| Lee, KM | 1 |
| Foo, KF | 1 |
| Ang, P | 1 |
| Ang, PT | 1 |
| Antonadou, D | 5 |
| Throuvalas, N | 3 |
| Petridis, A | 2 |
| Bolanos, N | 2 |
| Sagriotis, A | 2 |
| Synodinou, M | 3 |
| Kanat, O | 1 |
| Evrensel, T | 1 |
| Baran, I | 1 |
| Coskun, H | 1 |
| Zarifoglu, M | 1 |
| Turan, OF | 1 |
| Kurt, E | 1 |
| Demiray, M | 1 |
| Gonullu, G | 1 |
| Manavoglu, O | 1 |
| Choi, NC | 1 |
| Veslemes, M | 1 |
| Milas, L | 7 |
| Lee, HK | 1 |
| Fossella, FV | 3 |
| Herbst, RS | 1 |
| Allen, PK | 2 |
| Stevens, CW | 2 |
| Lu, C | 1 |
| Zinner, RG | 1 |
| Papadimitrakopoulou, VA | 1 |
| Kies, MS | 1 |
| Blumenschein, GR | 1 |
| Pisters, KM | 1 |
| Glisson, BS | 1 |
| Kurie, J | 2 |
| Kaplan, B | 2 |
| Garza, VP | 1 |
| Mooring, D | 1 |
| Cox, JD | 2 |
| Brooks, C | 1 |
| Famiglietti, R | 1 |
| Cox, J | 1 |
| Frank, S | 1 |
| Forster, K | 1 |
| Cengiz, M | 1 |
| Onal, C | 1 |
| Yildiz, F | 1 |
| Zorlu, AF | 1 |
| Thongprasert, S | 1 |
| Chewaskulyong, B | 1 |
| Mehta, V | 2 |
| Rosenman, J | 1 |
| Scott, C | 1 |
| Smith, C | 1 |
| Axelrod, R | 1 |
| Byhardt, R | 2 |
| Juan, O | 1 |
| Rocher, A | 1 |
| Sánchez, A | 1 |
| Sánchez, JJ | 1 |
| Alberola, V | 1 |
| Rosenman, JG | 1 |
| Socinski, MA | 1 |
| Chang, JY | 1 |
| Wu, X | 1 |
| Travis, E | 1 |
| Spitz, MR | 1 |
| Wynn, RB | 1 |
| Bensadoun, RJ | 1 |
| Schubert, MM | 1 |
| Lalla, RV | 1 |
| Keefe, D | 1 |
| Pataer, A | 1 |
| Fanale, MA | 1 |
| Roth, JA | 1 |
| Swisher, SG | 1 |
| Hunt, KK | 1 |
| Dest, VM | 1 |
| Mell, LK | 1 |
| Malik, R | 1 |
| Swann, RS | 1 |
| Koukourakis, M | 1 |
| Mundt, AJ | 1 |
| Garces, YI | 1 |
| Okuno, SH | 1 |
| Schild, SE | 1 |
| Mandrekar, SJ | 1 |
| Bot, BM | 1 |
| Martens, JM | 1 |
| Wender, DB | 1 |
| Soori, GS | 1 |
| Moore, DF | 1 |
| Kozelsky, TF | 1 |
| Jett, JR | 1 |
| Swann, S | 1 |
| Hunter, N | 4 |
| Reid, BO | 1 |
| Thames, HD | 2 |
| Ito, H | 1 |
| Betticher, DC | 1 |
| Anderson, H | 1 |
| Ranson, M | 1 |
| Meely, K | 1 |
| Oster, W | 1 |
| Thatcher, N | 1 |
| Schiller, JH | 4 |
| Storer, B | 2 |
| Berlin, J | 1 |
| Wittenkeller, J | 1 |
| Larson, M | 3 |
| Pharo, L | 1 |
| Berry, W | 1 |
| Tannehill, SP | 2 |
| Mehta, MP | 4 |
| Pellet, J | 1 |
| Kinsella, TJ | 1 |
| Taylor, CW | 1 |
| Wang, LM | 1 |
| List, AF | 1 |
| Fernandes, D | 1 |
| Paine-Murrieta, GD | 1 |
| Johnson, CS | 1 |
| Capizzi, RL | 1 |
| Stefanaki, I | 1 |
| Frangiadaki, C | 1 |
| Armenaki, A | 1 |
| Georgoulias, V | 1 |
| Koumandakis, E | 1 |
| Kranidis, A | 1 |
| Helidonis, E | 1 |
| Lindemann, K | 1 |
| Grdina, DJ | 2 |
| Kataoka, Y | 2 |
| Murley, JS | 2 |
| Selvaggi, G | 1 |
| Belani, CP | 1 |
| Gridelli, C | 3 |
| Cigolari, S | 1 |
| Maiorino, A | 1 |
| Ianniello, GP | 1 |
| Brancaccio, L | 1 |
| Rossi, A | 2 |
| De Cataldis, G | 1 |
| Pedicini, T | 1 |
| Maiorino, L | 1 |
| Barletta, E | 2 |
| Di Lanno, M | 1 |
| Bilancia, D | 1 |
| Crispino, C | 1 |
| Barzelloni, ML | 2 |
| Masullo, P | 1 |
| D'Aniello, R | 2 |
| Manzione, L | 1 |
| Castiglione, F | 1 |
| Porcile, G | 1 |
| Guida, C | 1 |
| Gatani, T | 1 |
| Fiore, F | 1 |
| de Bellis, M | 1 |
| Scognamiglio, F | 1 |
| Johnson, PW | 1 |
| Muers, MF | 1 |
| Peake, MD | 1 |
| Poulter, KM | 1 |
| Gurney, EM | 1 |
| Napp, VV | 1 |
| Hepburn, PM | 1 |
| Brown, JM | 1 |
| Genvresse, I | 1 |
| Lange, C | 1 |
| Schanz, J | 1 |
| Schweigert, M | 1 |
| Harder, H | 1 |
| Possinger, K | 1 |
| Späth-Schwalbe, E | 1 |
| Coliarakis, N | 1 |
| Athanassiou, H | 1 |
| Kouveli, A | 1 |
| Verigos, C | 1 |
| Georgakopoulos, G | 1 |
| Panoussaki, K | 1 |
| Karageorgis, P | 1 |
| Weichselbaum, RR | 1 |
| Axelrod, RS | 1 |
| Friedland, DP | 1 |
| Hauck, W | 1 |
| Rose, LJ | 1 |
| Chapman, AE | 1 |
| Grubbs, S | 1 |
| Deshields, M | 1 |
| Allen, P | 1 |
| Zinner, R | 1 |
| Papadimitrakopoulou, V | 1 |
| Khuri, F | 1 |
| Glisson, B | 1 |
| Pisters, K | 1 |
| Herbst, R | 1 |
| Ro, J | 1 |
| Hong, WK | 1 |
| Arquette, M | 1 |
| Govindan, R | 1 |
| Garfield, D | 1 |
| Gillenwater, H | 1 |
| Socinski, M | 1 |
| Yuhas, JM | 1 |
| Rubin, P | 1 |
| Salazar, O | 1 |
| Zagars, G | 1 |
| Constine, LS | 1 |
| Keys, H | 1 |
| Poulter, CA | 1 |
| Van Ess, JD | 1 |
| Kanclerz, A | 1 |
| Chapman, JD | 1 |
| Glover, D | 1 |
| Glick, JH | 1 |
| Weiler, C | 1 |
| Fox, K | 1 |
| Guerry, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase III Randomized Study of Amifostine Mucosal Protection for Patients With Favorable Performance Inoperable Stage II-III A/B Non-Small Cell Lung Cancer (NSCLC) Receiving Sequential Induction and Concurrent Hyperfractionated Radiotherapy With Paclitax[NCT00003313] | Phase 3 | 243 participants (Actual) | Interventional | 1998-09-30 | Completed | ||
| A Phase III Comparison Between Concurrent Chemotherapy Plus Radiotherapy and Concurrent Chemotherapy Plus Radiotherapy Followed by Surgical Resection for Stage IIIA (N2) Non-Small Cell Lung Cancer[NCT00002550] | Phase 3 | 429 participants (Actual) | Interventional | 1994-03-31 | Completed | ||
| A Phase II Trial of Tislelizumab as Consolidation Therapy in Patients With Locally Advanced or Oligometastatic Non-Small Cell Lung Cancer Who Have Not Progressed Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent [NCT05468242] | Phase 2 | 60 participants (Anticipated) | Interventional | 2022-02-01 | Recruiting | ||
| Phase I-II Study of Topotecan and Paclitaxel Followed by High-Dose Thoracic Radiation Therapy With Concomitant Cisplatin/Etoposide and Amifostine in Limited-Stage Small Cell Lung Cancer[NCT00006012] | Phase 1/Phase 2 | 73 participants (Actual) | Interventional | 2001-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
19 reviews available for amifostine anhydrous and Lung Neoplasms
| Article | Year |
|---|---|
Potential of Amifostine for Chemoradiotherapy and Radiotherapy-associated Toxicity Reduction in Advanced NSCLC: A Meta-Analysis.
Topics: Amifostine; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Chi-Square Distribution; Humans; Lung | 2016 |
Effect of amifostine on survival among patients treated with radiotherapy: a meta-analysis of individual patient data.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Non-S | 2011 |
[Effect of amifostine on locally advanced non-small cell lung cancer patients treated with radiotherapy: a meta-analysis of randomized controlled trials].
Topics: Amifostine; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Radiation-Protective Agents; Ran | 2012 |
Concurrent administration of Docetaxel and Stealth liposomal doxorubicin with radiotherapy in non-small cell lung cancer : excellent tolerance using subcutaneous amifostine for cytoprotection.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined | 2002 |
Radioprotective effect of amifostine in radiation pneumonitis.
Topics: Amifostine; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic | 2003 |
Open label multicenter trial of subcutaneous amifostine (Ethyol) in the prevention of radiation induced esophagitis and pneumonitis in patients with measurable, unresectable non-small cell lung cancer.
Topics: Amifostine; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; | 2004 |
Randomized phase II study of amifostine mucosal protection by either subcutaneous injection or rapid IV bolus for patients with inoperable stage II-IIIA/B or stage IV non-small cell lung cancer with oligometastases receiving concurrent radiochemotherapy w
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell L | 2004 |
Does more aggressive therapy improve outcomes in the treatment of unresectable stage III non-small cell lung cancer?
Topics: Amifostine; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combine | 2005 |
Pulmonary toxicity associated with the treatment of non-small cell lung cancer and the effects of cytoprotective strategies.
Topics: Amifostine; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combine | 2005 |
Treatment-related esophagitis.
Topics: Amifostine; Antineoplastic Agents; Dose Fractionation, Radiation; Esophagitis; Humans; Lung Neoplasm | 2005 |
Amifostine in the management of radiation-induced and chemo-induced mucositis.
Topics: Amifostine; Antineoplastic Agents; Combined Modality Therapy; Esophagitis; Evidence-Based Medicine; | 2006 |
Radioprotectants: adding quality of life to survivorship?
Topics: Amifostine; Combined Modality Therapy; Head and Neck Neoplasms; Humans; Lung Neoplasms; Neoplasms; O | 2006 |
Effect of amifostine on response rates in locally advanced non-small-cell lung cancer patients treated on randomized controlled trials: a meta-analysis.
Topics: Amifostine; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Humans; Lung Neoplasms; Radiation- | 2007 |
Amifostine and radiation therapy: past, present, and future.
Topics: Amifostine; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Humans; Lung Neoplasms; Neopl | 1996 |
Protection of normal tissues from the cytotoxic effects of radiation therapy: focus on amifostine.
Topics: Amifostine; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Clinical Trials, Phase II as T | 1998 |
Carboplatin and paclitaxel in non-small cell lung cancer: the role of amifostine.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carboplatin; Carci | 1999 |
Amifostine and combined-modality therapeutic approaches.
Topics: Amifostine; Clinical Trials as Topic; Combined Modality Therapy; Cytoprotection; Female; Head and Ne | 1999 |
Future directions in non-small cell lung cancer.
Topics: Amifostine; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Cytopro | 1999 |
The potential role of amifostine in the treatment of non small cell lung cancer.
Topics: Amifostine; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Humans; Lung Neoplasms; Radia | 2000 |
33 trials available for amifostine anhydrous and Lung Neoplasms
| Article | Year |
|---|---|
Randomized phase 2 study of subcutaneous amifostine versus epoetin-alpha given 3 times weekly during concurrent chemotherapy and hyperfractionated radiotherapy for limited-disease small cell lung cancer.
Topics: Aged; Amifostine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2008 |
[Prophylactic effect of amifostine on oxaliplatin-related neurotoxicity in patients with digestive tract tumors].
Topics: Amifostine; Antineoplastic Agents; Colonic Neoplasms; Female; Humans; Liver Neoplasms; Lung Neoplasm | 2008 |
Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carbopla | 2012 |
Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carbopla | 2012 |
Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carbopla | 2012 |
Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carbopla | 2012 |
Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carbopla | 2012 |
Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carbopla | 2012 |
Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carbopla | 2012 |
Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carbopla | 2012 |
Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carbopla | 2012 |
Concurrent administration of Docetaxel and Stealth liposomal doxorubicin with radiotherapy in non-small cell lung cancer : excellent tolerance using subcutaneous amifostine for cytoprotection.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined | 2002 |
A phase III randomized evaluation of amifostine in stage IIIA/IIIB non-small cell lung cancer patients receiving concurrent carboplatin, paclitaxel, and radiation therapy followed by gemcitabine and cisplatin intensification: preliminary findings.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non | 2002 |
Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non | 2003 |
Effect of amifostine on toxicities associated with radiochemotherapy in patients with locally advanced non-small-cell lung cancer.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell L | 2003 |
Protective effect of amifostine against toxicity of paclitaxel and carboplatin in non-small cell lung cancer: a single center randomized study.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell L | 2003 |
Amifostine reduces radiochemotherapy-induced toxicities in patients with locally advanced non-small cell lung cancer.
Topics: Aged; Amifostine; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modal | 2003 |
Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Amifostine; Antineoplastic Combined Chemotherapy Pr | 2004 |
Heterogeneous planning for homogeneous protocols.
Topics: Amifostine; Clinical Protocols; Humans; Lung Neoplasms; Patient Care Planning; Radiation-Protective | 2004 |
Study of cisplatin-vinblastine plus amifostine in patients with locally advanced or metastatic non-small cell lung cancer.
Topics: Adult; Aged; Amifostine; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cytoprote | 2004 |
Open label multicenter trial of subcutaneous amifostine (Ethyol) in the prevention of radiation induced esophagitis and pneumonitis in patients with measurable, unresectable non-small cell lung cancer.
Topics: Amifostine; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; | 2004 |
Randomized phase II study of amifostine mucosal protection by either subcutaneous injection or rapid IV bolus for patients with inoperable stage II-IIIA/B or stage IV non-small cell lung cancer with oligometastases receiving concurrent radiochemotherapy w
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell L | 2004 |
Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01.
Topics: Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small- | 2005 |
Influence of the cyto-protective agent amifostine on the pharmacokinetics of low-dose Paclitaxel.
Topics: Amifostine; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Dose-Response Relatio | 2005 |
Mutagen sensitivity may predict lung protection by amifostine for patients with locally advanced non-small cell lung cancer treated by chemoradiotherapy.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Non-S | 2005 |
Phase I North Central Cancer Treatment Group Trial-N9923 of escalating doses of twice-daily thoracic radiation therapy with amifostine and with alternating chemotherapy in limited stage small-cell lung cancer.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisp | 2007 |
Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: a randomised phase II study.
Topics: Adult; Aged; Amifostine; Antineoplastic Agents; Bone Marrow Diseases; Carboplatin; Carcinoma, Non-Sm | 1995 |
Amifostine, cisplatin, and vinblastine in metastatic non-small-cell lung cancer: a report of high response rates and prolonged survival.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell L | 1996 |
High-dose cisplatin and vinblastine plus amifostine for metastatic non-small cell lung cancer.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplati | 1996 |
Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-small-cell lung cancer: results of a phase II trial.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell L | 1997 |
Fractionated carboplatin radiosensitization: a phase I dose-escalation study.
Topics: Adult; Aged; Amifostine; Antineoplastic Agents; Carboplatin; Combined Modality Therapy; Erythropoiet | 1998 |
Amifostine plus cisplatin plus vinorelbine in the treatment of advanced non small cell lung cancer: a multicenter phase II study.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell L | 2000 |
Thoracic radiotherapy and daily vinorelbine as radiosensitizer in locally advanced non small cell lung cancer: a phase I study.
Topics: Adenocarcinoma; Aged; Amifostine; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; | 2000 |
A randomized trial of amifostine as a cytoprotective agent in patients receiving chemotherapy for small cell lung cancer.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Sma | 2001 |
Randomized phase III trial of radiation treatment +/- amifostine in patients with advanced-stage lung cancer.
Topics: Acute Disease; Amifostine; Esophagitis; Female; Humans; Lung Neoplasms; Male; Middle Aged; Premedica | 2001 |
Phase II: trial of twice weekly amifostine in patients with non-small cell lung cancer treated with chemoradiotherapy.
Topics: Acute Disease; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcin | 2002 |
Exploring the role of the radioprotector amifostine in locally advanced non-small cell lung cancer: Radiation Therapy Oncology Group trial 98-01.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined | 2002 |
Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: preliminary results.
Topics: Adult; Aged; Amifostine; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Combined | 2002 |
Radiotherapy or chemotherapy followed by radiotherapy with or without amifostine in locally advanced lung cancer.
Topics: Acute Disease; Amifostine; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality | 2002 |
Phase II evaluation of amifostine as an esophageal mucosal protectant in the treatment of limited-stage small cell lung cancer with chemotherapy and twice-daily radiation.
Topics: Amifostine; Antineoplastic Agents; Carcinoma, Small Cell; Combined Modality Therapy; Dose-Response R | 2002 |
Systemic hemibody irradiation for overt and occult metastases.
Topics: Amifostine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; C | 1985 |
24 other studies available for amifostine anhydrous and Lung Neoplasms
| Article | Year |
|---|---|
Nicaraven reduces cancer metastasis to irradiated lungs by decreasing CCL8 and macrophage recruitment.
Topics: Amifostine; Animals; Antioxidants; Cell Line, Tumor; Chemokine CCL8; Gamma Rays; Humans; Lung; Lung | 2018 |
Computed tomography assessment of lung density in patients with lung cancer treated with accelerated hypofractionated radio-chemotherapy supported with amifostine.
Topics: Aged; Amifostine; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; | 2009 |
Quality of life supersedes the classic prognosticators for long-term survival in locally advanced non-small-cell lung cancer: an analysis of RTOG 9801.
Topics: Aged; Amifostine; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Karnofsky P | 2009 |
In regard to Antonadou et al. Randomized trial investigating the effects of daily amifostine in addition to radiation therapy in 146 patients with advanced lung cancers.
Topics: Amifostine; Clinical Trials as Topic; Humans; Lung Neoplasms; Radiation-Protective Agents; Random Al | 2002 |
Proceedings of the 2nd International Cytoprotection Investigators' Congress. June 6-9, 2002. St Thomas, US Virgin Islands, USA.
Topics: Amifostine; Animals; Breast Neoplasms; Cytoprotection; Female; Head and Neck Neoplasms; Humans; Lung | 2002 |
Down-regulation of intestinal-type alkaline phosphatase in the tumor vasculature and stroma provides a strong basis for explaining amifostine selectivity.
Topics: Alkaline Phosphatase; Amifostine; Antigens, Neoplasm; Biomarkers, Tumor; Breast; Breast Neoplasms; C | 2002 |
The relationship between local dose and loss of function for irradiated lung.
Topics: Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplati | 2003 |
Comment on: 'Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients' Radiother Oncol 70: 261-264, 2004 by Dr Rades et al.
Topics: Amifostine; Head and Neck Neoplasms; Humans; Lung Neoplasms; Radiation-Protective Agents | 2004 |
Can the use of amifostine improve cure rates for patients with advanced non-small cell lung cancer?
Topics: Amifostine; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Hum | 2004 |
Reduction of treatment breaks and radiation-induced esophagitis and pneumonitis using amifostine in unresectable non-small cell lung cancer patients receiving definitive concurrent chemotherapy and radiation therapy: a prospective community-based clinical
Topics: Amifostine; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topi | 2005 |
Amifostine in chemoradiation therapy for non-small cell lung cancer: review of experience and design of a phase II trial assessing subcutaneous and intravenous bolus administration.
Topics: Amifostine; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topi | 2005 |
What should the optimal timing be for amifostine administration relative to radiation and chemotherapy?
Topics: Amifostine; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Administration Schedule; | 2005 |
Induction of apoptosis in human lung cancer cells following treatment with amifostine and an adenoviral vector containing wild-type p53.
Topics: Adenoviridae; Amifostine; Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Prote | 2006 |
Clinically meaningful differences in patient-reported outcomes with amifostine in combination with chemoradiation for locally advanced non-small-cell lung cancer: an analysis of RTOG 9801.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell L | 2008 |
Protective effects of S-2-(3-aminopropylamino)ethylphosphorothioic acid against radiation damage of normal tissues and a fibrosarcoma in mice.
Topics: Amifostine; Animals; Dose-Response Relationship, Drug; Female; Fibrosarcoma; Gamma Rays; Jejunum; Lu | 1982 |
Effect of tumor size on S-2-(3-aminopropylamino)ethylphosphorothioic acid and misonidazole alteration of tumor response to cyclophosphamide.
Topics: Amifostine; Animals; Cyclophosphamide; Drug Interactions; Drug Therapy, Combination; Extremities; Fe | 1983 |
Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumour cells is maintained.
Topics: Amifostine; Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cell Culture | 1997 |
Administration of the cytoprotectant amifostine.
Topics: Amifostine; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Kidney | 1998 |
Chemopreventive doses of amifostine confer no cytoprotection to tumor nodules growing in the lungs of mice treated with cyclophosphamide.
Topics: Amifostine; Animals; Anticarcinogenic Agents; Antimutagenic Agents; Antineoplastic Agents, Alkylatin | 1999 |
Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Amifostine; Antihypertensive Agents; Antineoplastic Com | 2001 |
Inhibition of spontaneous metastases formation by amifostine.
Topics: Amifostine; Angiostatins; Animals; Blotting, Western; Cell Division; Dose-Response Relationship, Dru | 2002 |
Differential protection of normal and malignant tissues against the cytotoxic effects of mechlorethamine.
Topics: Amifostine; Animals; Bone Marrow; Drug Tolerance; Female; Lethal Dose 50; Lung Neoplasms; Mechloreth | 1979 |
Influence of misonidazole, SR-2508, RSU-1069 and WR-2721 on spontaneous metastases in C57BL mice.
Topics: Amifostine; Animals; Etanidazole; Lung Neoplasms; Male; Melanoma; Mice; Mice, Inbred C57BL; Misonida | 1988 |
WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Evaluation; | 1987 |